Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Astrocytoma/Astrocytic tumors
Stage/Subtype:  childhood high-grade untreated astrocytoma or other tumor of glial origin
Country:  U.S.A.
Trial Type:  Treatment
Results 1-14 of 14 for your search:
Start Over
Crizotinib in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL0912, NCI-2011-01937, CDR0000647587, COG-ADVL0912, NCT01182896, P10666, NCT00939770
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: PBTC-033, NCI-2012-00082, 12-C-0213, CDR0000717423, NCT01507324, P12978, NCT01514201
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase: Phase I
Type: Treatment
Age: 3 to 22
Trial IDs: 07-098, NCI-2015-00672, NCT00634231
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 37 months to 21 years
Trial IDs: ADVL1217, NCI-2013-01602, COG-ADVL1217, NCT01922076
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Lenalidomide and Radiation Therapy in Treating Younger Patients with Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: 10-C-0219, NCI-2011-02539, 100219, CDR0000687467, NCI-10-C-0219, NCT01226940, 8449, NCT01222754
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid or Central Nervous System Tumors
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Fluorine F 18 Fluorodopa PET/MRI in Predicting Response in Younger Patients with Central Nervous System Tumors
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 21 and under
Trial IDs: 201303069, NCI-2013-00822, NCT01999270
Pembrolizumab in Treating Younger Patients with Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 1 to 21
Trial IDs: PBTC-045, NCI-2015-00130, NCT02359565
Start Over